Department of Pharmacy Practice, Wayne State University, Detroit, Michigan 48201, USA.
J Stroke Cerebrovasc Dis. 2010 Jan;19(1):40-8. doi: 10.1016/j.jstrokecerebrovasdis.2009.03.006.
Circadian pattern for the onset of acute ischemic stroke has been described; however, data assessing an association between thrombolytic therapy efficacy and circadian rhythm are limited. We assessed the relationship between the time of stroke onset and neurologic outcomes after thrombolytic therapy for acute ischemic stroke in the National Institute of Neurological Disorders and Stroke (NINDS) Recombinant Tissue Plasminogen Activator (rt-PA) Stroke Trial.
We conducted exploratory, post hoc analysis of 624 patients in the NINDS rt-PA Stroke Trial. Variables assessed included presenting time of day (4- and 6-hour time blocks), outcome variables, stroke subtypes, treatment assignment, and biological markers. Outcome variables included 3-month mortality, clinical outcome at 3 months, intracranial hemorrhage (ICH), computed tomography lesion volume at 3 months, and deterioration at 24 hours.
The distribution of patients in the time blocks was balanced between the rt-PA and placebo groups. There was not a clear circadian variation in the stroke onset time. There were no associations detected between stroke onset time and clinical outcome, computed tomography lesion volume, and asymptomatic hemorrhage. Patients treated with rt-PA whose stroke onset was between 0401 and 0800 hours had less symptomatic ICH, whereas those who received rt-PA between 0000 and 0400 hours had a 43% incidence of symptomatic ICH. Patients in the placebo group who had stroke onset between 1801 and 2400 hours had lower chances for neurologic deterioration. Patients who had a stroke between 0001 and 0400 hours had the highest fibrinogen concentrations.
We did not find a circadian pattern to time of day of stroke onset in the patients included in the NINDS rt-PA Stroke Trial. The effect of rt-PA treatment on favorable outcome was independent of time of day of stroke onset. Patients who received rt-PA between 4 and 8 am were less likely to develop symptomatic ICH.
已经描述了急性缺血性脑卒中发作的昼夜节律模式;然而,评估溶栓治疗效果与昼夜节律之间关系的数据有限。我们评估了国立神经病学与卒中研究所(NINDS)重组组织型纤溶酶原激活剂(rt-PA)急性缺血性脑卒中试验中脑卒中发病时间与溶栓治疗后神经功能结局之间的关系。
我们对 NINDS rt-PA 脑卒中试验中的 624 例患者进行了探索性、事后分析。评估的变量包括一天中的就诊时间(4 小时和 6 小时时间块)、结局变量、脑卒中亚型、治疗分配和生物标志物。结局变量包括 3 个月死亡率、3 个月临床结局、颅内出血(ICH)、3 个月时计算机断层扫描(CT)病变体积和 24 小时恶化。
在 rt-PA 和安慰剂组之间,患者在时间块中的分布是平衡的。脑卒中发病时间没有明显的昼夜变化。未检测到脑卒中发病时间与临床结局、CT 病变体积和无症状性出血之间的关联。发病时间在 0401 至 0800 之间的 rt-PA 治疗患者的症状性 ICH 发生率较低,而发病时间在 0000 至 0400 之间的患者则有 43%的症状性 ICH 发生率。安慰剂组中发病时间在 1801 至 2400 之间的患者发生神经功能恶化的几率较低。发病时间在 0001 至 0400 之间的患者纤维蛋白原浓度最高。
我们在 NINDS rt-PA 脑卒中试验中纳入的患者中未发现脑卒中发病时间存在昼夜模式。rt-PA 治疗对良好结局的影响独立于脑卒中发病时间。在上午 4 点至 8 点接受 rt-PA 治疗的患者发生症状性 ICH 的可能性较小。